



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

T02-013-1  
RFB

Applicants: Chen et al.

Docket No.: 11134-013-999

Serial No: 10/705,173

Group Art Unit: 1625

Filed: November 6, 2003

Examiner: Aulakh, Charanjit

For: FUSED HETEROCYCLIC COMPOUNDS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**STATEMENT UNDER 37 C.F.R. 3.73(b)**

Amgen Inc. (hereinafter "Amgen"), a corporation of the State of Delaware having a place of business at One Amgen Center Drive, Thousand Oaks, California, 91320, is the assignee of the entire right, title, and interest in the above-identified U.S. patent application. A chain of title from the inventors of the above-identified application to Amgen Inc. is shown below.

1. From inventors Xi Chen, Xiaqi Chen, Pingchen Fan, Juan Jaen, Leping Li, and Jeffrey Thomas Mihalic To: Tularik, Inc. the assignment recorded April 9, 2004, in the USPTO at Reel 015202, Frame 0725.
2. From Tularik, Inc. To: Arrow Acquisition, LLC the assignment recorded June 7, 2005, in the USPTO at Reel 016309, Frame 0003.
3. From Arrow Acquisition, LLC To: Amgen SF, LLC the assignment recorded June 7, 2005, in the USPTO at Reel 016309, Frame 0812.
4. From Amgen SF, LLC To: Amgen Inc. the assignment recorded October 18, 2005, in the USPTO at Reel 016871, Frame 0736.

The undersigned, whose title is supplied below, is empowered to sign this statement on behalf of Amgen.

**REVOCATION OR PREVIOUS POWER OF ATTORNEY AND  
NEW POWER OF ATTORNEY BY ASSIGNEE**

Amgen hereby revokes all previous powers of attorney given in the above-identified application and hereby appoints the registered practitioners at Customer Number **21069** to prosecute this application, to make and to transact all business in the Patent and Trademark Office connected therewith.

**REQUEST FOR CHANGE OF CORRESPONDENCE ADDRESS**

Please send all future correspondence and direct telephone calls to Customer Number **20583**.

Respectfully submitted,

Date June 27, 2006

By: Stuart L. Watt  
Stuart L. Watt, Vice President, Law  
AMGEN INC., Assignee